Careprost vs Latisse: A Complete Comparison
Author : Emma Andersson | Published On : 21 May 2026
Long, full eyelashes have become one of the most sought-after cosmetic goals, and two prescription-grade treatments dominate the conversation: Careprost and Latisse. Both products promise to deliver longer, thicker, and darker lashes — and both deliver on that promise. But they differ significantly in price, availability, brand history, and a few practical details that matter to real users. This article breaks down everything you need to know before choosing between them.
What Are They?
Latisse
Latisse is a prescription eyelash growth treatment manufactured by Allergan (AbbVie). It was the first FDA-approved treatment for hypotrichosis (inadequate or thin eyelashes), receiving approval in 2008. It is widely regarded as the gold standard in lash growth serums and is available through licensed physicians and dermatologists in the United States.
Careprost
Careprost is manufactured by Sun Pharmaceutical Industries, an Indian pharmaceutical company. It contains the same active ingredient as Latisse and was originally developed as a treatment for glaucoma — reducing intraocular pressure. Careprost is widely used across Asia, Eastern Europe, and other international markets, and has gained a significant following among cost-conscious consumers in the West who obtain it through international online pharmacies.
The Active Ingredient: Bimatoprost
At the heart of both products is bimatoprost 0.03%, a synthetic prostaglandin analogue. This molecule was originally used in ophthalmology to lower eye pressure in glaucoma patients. Clinicians noticed a side effect: patients using it developed noticeably longer and darker lashes. Allergan harnessed this discovery and brought Latisse to market.
Both Careprost and Latisse contain bimatoprost at the same concentration. This is the key point of the entire debate — the core chemistry is identical.
Key Differences
| Feature | Latisse | Careprost |
|---|---|---|
| Manufacturer | Allergan (AbbVie), USA | Sun Pharma, India |
| FDA Approval | Yes (2008) | No (not approved for sale in the US) |
| Active Ingredient | Bimatoprost 0.03% | Bimatoprost 0.03% |
| Price (per 3 mL) | ~$150–$200 | ~$15–$30 |
| Availability | US prescription pharmacies | International online pharmacies |
| Applicator Brushes | Included (one per use) | Included (reusable) |
| Preservative | Benzalkonium chloride | Benzalkonium chloride |
| Clinical Studies | Extensive (FDA-level) | Limited independent studies |
How to Use Both Products
Application is nearly identical for both serums:
- Remove all makeup and contact lenses before applying.
- Using the provided applicator brush (or a fine eyeliner brush), draw a thin line along the upper lash line — from the inner corner to the outer corner.
- Blot any excess that runs onto the skin to minimize unwanted hair growth.
- Apply once nightly, before bed.
- Do not apply to the lower lash line directly; the product will migrate there through natural eye blinking.
Results typically become visible within 4–8 weeks, with full results at 12–16 weeks. If use is discontinued, lashes gradually return to their previous state within a few months.
Efficacy: Do They Work the Same?
In theory, yes. Because both contain the same active molecule at the same percentage, the biological mechanism is identical. Bimatoprost extends the anagen (growth) phase of the hair cycle, allowing lashes to grow longer before they shed, and stimulates more follicles to enter the active growth phase simultaneously.
In practice, many users report virtually indistinguishable results between the two. However, Latisse has the edge in clinical documentation — it has been through rigorous FDA trials that Careprost simply hasn't undergone in the United States. That said, bimatoprost itself (as an ophthalmic drug for glaucoma) has a long and well-studied safety record globally.
Side Effects and Risks
Both products carry similar risk profiles due to their shared active ingredient:
- Iris pigmentation changes — Prolonged contact with the iris can cause permanent darkening in people with light-colored eyes (hazel or green). This is a known risk, particularly for those who get the solution directly in the eye.
- Eyelid skin darkening — Hyperpigmentation along the lash line is common and is usually reversible upon discontinuation.
- Eye redness or irritation — Mild and typically transient.
- Unwanted hair growth — If serum drips onto cheek skin repeatedly, fine hairs may grow in that area.
- Dry eyes — Some users report increased dryness.
- Lowered intraocular pressure — Clinically insignificant for most healthy users, but worth noting for those with underlying eye conditions.
Proper application technique — applying only to the upper lash line and blotting excess — minimizes most of these risks.
Cost and Accessibility
This is where the two products diverge most dramatically.
Latisse costs between $150 and $200 for a 3 mL bottle (roughly a month's supply), available only with a prescription in the United States. Insurance rarely covers it, as it is considered cosmetic. Over a year of consistent use, costs can exceed $1,800.
Careprost can be purchased for as little as $15–$30 per 3 mL bottle through international online pharmacies. This makes it roughly 10 times cheaper than Latisse for an identical volume of product. However, it is not FDA-approved for sale in the United States, meaning it exists in a regulatory grey area and is not available at US pharmacies.
Regulatory and Safety Considerations
This is perhaps the most important distinction for US-based consumers. Latisse is the only bimatoprost-based eyelash treatment with FDA approval. Purchasing Careprost online from overseas pharmacies carries certain risks:
- Counterfeit products are a real concern with unverified online suppliers.
- No regulatory oversight on manufacturing standards for imported versions.
- No physician supervision, which matters if side effects arise.
That said, Careprost manufactured by Sun Pharma is a legitimate pharmaceutical product sold legally in many countries. The concern is less about the genuine product and more about the integrity of the supply chain when purchasing from unverified international sources.
Which One Should You Choose?
Choose Latisse if:
- You want an FDA-approved product with extensive clinical documentation.
- You prefer physician oversight and a domestic supply chain.
- Budget is not a primary concern.
- You want a product you can discuss openly with your doctor.
Choose Careprost if:
- Cost is a significant factor for you.
- You have access to verified, reputable international pharmacies.
- You've done your research and are comfortable with the regulatory trade-offs.
- You live outside the United States, where Careprost is legally sold.
The Bottom Line
Careprost and Latisse are, at their biochemical core, the same treatment. Both use bimatoprost 0.03% to produce real, clinically meaningful lash growth. The differences lie in brand prestige, FDA approval status, clinical documentation, price, and supply chain reliability. For those in the US who prioritize safety, regulatory compliance, and physician involvement, Latisse is the unambiguous choice. For budget-conscious individuals worldwide who are comfortable navigating international pharmaceutical channels, Careprost offers a compelling and largely comparable alternative.
As with any prescription-strength product, consulting a healthcare provider before starting treatment is always advisable — regardless of which brand you choose.
